Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Therapeutic performance of recombinant antibodies relies on two independent mechanisms: antigen recognition and Fc-mediated antibody effector functions. Interaction of Fc-fragment with different FcR triggers antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity and determines longevity of the antibody in serum. In context of therapeutic antibodies FcγRs play the most important role. It has been demonstrated that the Fc-attached sugar moiety is essential for IgG effector functionality, dictates its affinity to individual FcγRs and determines binding to different receptor classes: activating or inhibitory. In this study, we systematically analyze effector functions of monoclonal IgG1 and its eight enzymatically engineered glycosylation variants. The analysis of interaction of glycovariants with FcRs was performed for single, as well as for antigen-bound antibodies and IgGs in a form of immune complex. In addition to functional properties we addressed impact of glycosylation on the structural properties of the tested glycovariants. We demonstrate a clear impact of glycosylation pattern on antibody stability and interaction with different FcγRs. Consistent with previous reports, deglycosylated antibodies failed to bind all Fcγ-receptors, with the exception of high affinity FcγRI. The FcγRII and FcγRIIIa binding activity of IgG1 was observed to depend on the galactosylation level, and hypergalactosylated antibodies demonstrated increased receptor interaction. Sialylation did not decrease the FcγR binding of the tested IgGs; in contrast, sialylation of antibodies improved binding to FcγRIIa and IIb. We demonstrate that glycosylation influences to some extent IgG1 interaction with FcRn. However, independent of glycosylation pattern the interaction of IgG1 with a soluble monomeric target surprisingly resulted in an impaired receptor binding. Here, we demonstrate, that immune complexes (IC), induced by multimeric ligand, compensated for the decreased affinity of target bound antibody towards FcRs, showing the importance of the IC-formation for the FcR- mediated effector functions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures










Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“More recently, Dashivets et al. studied enzymatically engineered glycosylation variants and showed that deglycosylated IgG1 had a slightly diminished binding to FcRn, with digalactosylated IgG demonstrating superior binding than monogalactosylated and agalactosylated variants (87).”
From Factors Affecting the FcRn-Mediated Transplacental Transfer of Antibodies and Implications for Vaccination in Pregnancy (2017) · cites this paper as [87]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346 · cited 1×
“[12,65,92] Interaction of the FcRn with IgGs was reported to be independent of the antibody oligosaccharide pattern.”
BackgroundScott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754 · cited 1×
“[85] Sialylated antibodies are believed to be the pro-active species in IVIG (Intravenous Immune Globulin), which suppresses autoantibodymediated inflammation by activating the inhibitory FcγRIIb and downstream negative signaling pathways.”
BackgroundBruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S., & Daëron, M. (2009) · Blood · doi:10.1182/blood-2008-09-179754 · Cited by 1,479
The Impact of Glycosylation on the Biological Function and Structure of Human Immunoglobulins
Arnold, J. N., Wormald, M. R., Sim, R. B., Rudd, P. M., & Dwek, R. A. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141702 · Cited by 1,307
Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,161
High-Density Miniaturized Thermal Shift Assays as a General Strategy for Drug Discovery
Pantoliano, M. W., Petrella, E. C., Kwasnoski, J. D., Lobanov, V. S., Myslik, J., Graf, E., Carver, T., Asel, E., Springer, B. A., Lane, P., et al. (2001) · SLAS Discovery · doi:10.1177/108705710100600609 · Cited by 893
Thermofluor-based high-throughput stability optimization of proteins for structural studies
Ericsson, U. B., Hallberg, B. M., DeTitta, G. T., Dekker, N., & Nordlund, P. (2006) · Analytical Biochemistry · doi:10.1016/j.ab.2006.07.027 · Cited by 839
Glycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829 · cited 1×
“More than 40 therapeutic mAbs and mAb fragments are approved and prescribed today [1,2], the majority being of the IgG isotype.[3] The IgG molecule consists of two light chains (two domains each) and two heavy chains (four domains each).”
BackgroundKrapp, S., Mimura, Y., Jefferis, R., Huber, R., & Sondermann, P. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)01250-0 · Cited by 674 · cited 1×
“[84] Impact of terminal sialic acid on the functionality of antibodies remains a controversial issue.”
BackgroundThe Thermal Stability of Immunoglobulin: Unfolding and Aggregation of a Multi-Domain Protein
Vermeer, A. W. P., & Norde, W. (2000) · Biophysical Journal · doi:10.1016/s0006-3495(00)76602-1 · Cited by 666
Identification of a receptor required for the anti-inflammatory activity of IVIG
Anthony, R. M., Wermeling, F., Karlsson, M. C. I., & Ravetch, J. V. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810163105 · Cited by 547
Terminal sugars of Fc glycans influence antibody effector functions of IgGs
Raju, T. S. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.007 · Cited by 521
Karsten, C. M., Pandey, M. K., Figge, J., Kilchenstein, R., Taylor, P. R., Rosas, M., McDonald, J. U., Orr, S. J., Berger, M., Petzold, D., et al. (2012) · Nature Medicine · doi:10.1038/nm.2862 · Cited by 479
Multiple Roles for the Major Histocompatibility Complex Class I– Related Receptor FcRn
Ghetie, V., & Ward, E. S. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.739 · Cited by 474 · cited 1×
“[12,65,92] Interaction of the FcRn with IgGs was reported to be independent of the antibody oligosaccharide pattern.”
BackgroundFc‐Receptors as Regulators of Immunity
Nimmerjahn, F., & Ravetch, J. V. (2007) · Advances in Immunology · doi:10.1016/s0065-2776(07)96005-8 · Cited by 418 · cited 1×
“It should also be mentioned, that the two heavy chains of the same IgGmolecule may carry different sugar moieties.[19,20] Multi-Angle Effector Function Analysis of Human Monoclonal IgG”
BackgroundGessner, J. E., Heiken, H., Tamm, A., & Schmidt, R. E. (1998) · Annals of Hematology · doi:10.1007/s002770050396 · Cited by 404
Scallon, B. J., Tam, S. H., McCarthy, S. G., Cai, A. N., & Raju, T. S. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2006.09.005 · Cited by 396
Post-translational Modifications Differentially Affect IgG1 Conformation and Receptor Binding
Houde, D., Peng, Y., Berkowitz, S. A., & Engen, J. R. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m900540-mcp200 · Cited by 393
Kanda, Y., Yamada, T., Mori, K., Okazaki, A., Inoue, M., Kitajima-Miyama, K., Kuni-Kamochi, R., Nakano, R., Yano, K., Kakita, S., et al. (2007) · Glycobiology · doi:10.1093/glycob/cwl057 · Cited by 372 · cited 1×
“[93] Comparison of binding activities of IgG1 glycovariants to FcRn obtained by SPR did not reveal any striking differences in binding activities, however bi-galactosylated antibodies showed slightly increased and deglycosylated IgG1 slightly decreased receptor interaction.”
BackgroundThe Carbohydrate at FcγRIIIa Asn-162
Ferrara, C., Stuart, F., Sondermann, P., Brünker, P., & Umaña, P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510171200 · Cited by 354
Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond
Hogarth, P. M., & Pietersz, G. A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd2909 · Cited by 348
The impact of glycosylation on monoclonal antibody conformation and stability
Zheng, K., Bantog, C., & Bayer, R. (2011) · mAbs · doi:10.4161/mabs.3.6.17922 · Cited by 342
Mimura, Y., Church, S., Ghirlando, R., Ashton, P. R., Dong, S., Goodall, M., Lund, J., & Jefferis, R. (2000) · Molecular Immunology · doi:10.1016/s0161-5890(00)00105-x · Cited by 329
Chemoenzymatic Glycoengineering of Intact IgG Antibodies for Gain of Functions
Huang, W., Giddens, J., Fan, S.-Q., Toonstra, C., & Wang, L.-X. (2012) · Journal of the American Chemical Society · doi:10.1021/ja3051266 · Cited by 308
Advances in the assessment and control of the effector functions of therapeutic antibodies
Jiang, X.-R., Song, A., Bergelson, S., Arroll, T., Parekh, B., May, K., Chung, S., Strouse, R., Mire-Sluis, A., & Schenerman, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3365 · Cited by 299
Antibody‐mediated modulation of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00910.x · Cited by 285 · cited 1×
“It has been reported that interaction of highly sialylated antibodies with the C-type lectin dendritic cell-specific intercellular adhesion molecule (ICAM)-grabbing non-integrin (DC-SIGN) triggers an anti-inflammatory pathway, resulting in up-regulation of the inhibitory FcγRIIb and down-regulation of the activating r…”
BackgroundBoyd, P. N., Lines, A. C., & Patel, A. K. (1995) · Molecular Immunology · doi:10.1016/0161-5890(95)00118-2 · Cited by 283 · cited 1×
“[33,34] However, in another report, sialic acid was demonstrated to either not effect or to improve antibody interaction with FcγRs [35] In addition to functional aspects, Fc glycan pattern has been demonstrated to have an impact on the conformational and structural properties of the antibody Fc, ensuring appropriate…”
BackgroundImpact of Immune Complex Size and Glycosylation on IgG Binding to Human FcγRs
Lux, A., Yu, X., Scanlan, C. N., & Nimmerjahn, F. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1200501 · Cited by 272
Isotype and glycoform selection for antibody therapeutics
Jefferis, R. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.03.021 · Cited by 252
In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity
Thomann, M., Schlothauer, T., Dashivets, T., Malik, S., Avenal, C., Bulau, P., Rüger, P., & Reusch, D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0134949 · Cited by 220
Self-citationInteraction sites on human IgG-Fc for FcγR: current models
Jefferis, R., & Lund, J. (2002) · Immunology Letters · doi:10.1016/s0165-2478(02)00019-6 · Cited by 220
Baker, K., Qiao, S.-W., Kuo, T. T., Aveson, V. G., Platzer, B., Andersen, J.-T., Sandlie, I., Chen, Z., de Haar, C., Lencer, W. I., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019037108 · Cited by 216
Yamaguchi, Y., Nishimura, M., Nagano, M., Yagi, H., Sasakawa, H., Uchida, K., Shitara, K., & Kato, K. (2006) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2005.10.002 · Cited by 204
Novel roles for the IgG Fc glycan
Anthony, R. M., Wermeling, F., & Ravetch, J. V. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06305.x · Cited by 186
Nimmerjahn, F., & Ravetch, J. V. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_86 · Cited by 180
Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies
Kayser, V., Chennamsetty, N., Voynov, V., Forrer, K., Helk, B., & Trout, B. L. (2011) · Biotechnology Journal · doi:10.1002/biot.201000091 · Cited by 172
Wang, W., Lu, P., Fang, Y., Hamuro, L., Pittman, T., Carr, B., Hochman, J., & Prueksaritanont, T. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.039453 · Cited by 166
Mannan binding lectin and its interaction with immunoglobulins in health and in disease
Arnold, J. N., Dwek, R. A., Rudd, P. M., & Sim, R. B. (2006) · Immunology Letters · doi:10.1016/j.imlet.2006.05.007 · Cited by 165
Park-Min, K.-H., Serbina, N. V., Yang, W., Ma, X., Krystal, G., Neel, B. G., Nutt, S. L., Hu, X., & Ivashkiv, L. B. (2007) · Immunity · doi:10.1016/j.immuni.2006.11.010 · Cited by 158
The Immunologic Functions of the Neonatal Fc Receptor for IgG
Rath, T., Kuo, T. T., Baker, K., Qiao, S.-W., Kobayashi, K., Yoshida, M., Roopenian, D., Fiebiger, E., Lencer, W. I., & Blumberg, R. S. (2013) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9768-y · Cited by 156
The role of sialic acid as a modulator of the anti-inflammatory activity of IgG
Böhm, S., Schwab, I., Lux, A., & Nimmerjahn, F. (2012) · Seminars in Immunopathology · doi:10.1007/s00281-012-0308-x · Cited by 152
Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies
Schlothauer, T., Rueger, P., Stracke, J. O., Hertenberger, H., Fingas, F., Kling, L., Emrich, T., Drabner, G., Seeber, S., Auer, J., et al. (2013) · mAbs · doi:10.4161/mabs.24981 · Cited by 136 · cited 1×
“Moreover, the chromatographic behavior of IgGs was shown to correlate with changes in the PK profile of FcRn transgenic mice.[63,64]”
BackgroundSelf-citationShibata‐Koyama, M., Iida, S., Misaka, H., Mori, K., Yano, K., Shitara, K., & Satoh, M. (2009) · Experimental Hematology · doi:10.1016/j.exphem.2008.11.006 · Cited by 123
The Role of FcRn in Antigen Presentation
Baker, K., Rath, T., Pyzik, M., & Blumberg, R. S. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00408 · Cited by 121 · cited 1×
“[12,65,92] Interaction of the FcRn with IgGs was reported to be independent of the antibody oligosaccharide pattern.”
BackgroundIgG-effector functions: “The Good, The Bad and The Ugly”
Kapur, R., Einarsdottir, H., & Vidarsson, G. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.01.015 · Cited by 118
A Systematic Comparison of Free and Bound Antibodies Reveals Binding-Related Conformational Changes
Sela-Culang, I., Alon, S., & Ofran, Y. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201493 · Cited by 115
Stracke, J., Emrich, T., Rueger, P., Schlothauer, T., Kling, L., Knaupp, A., Hertenberger, H., Wolfert, A., Spick, C., Lau, W., et al. (2014) · mAbs · doi:10.4161/mabs.29601 · Cited by 112 · cited 1×
“Moreover, the chromatographic behavior of IgGs was shown to correlate with changes in the PK profile of FcRn transgenic mice.[63,64]”
BackgroundSelf-citationEffects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys
Leabman, M. K., Meng, Y. G., Kelley, R. F., DeForge, L. E., Cowan, K. J., & Iyer, S. (2013) · mAbs · doi:10.4161/mabs.26436 · Cited by 110
Bypassing glycosylation: engineering aglycosylated full-length IgG antibodies for human therapy
Jung, S. T., Kang, T. H., Kelton, W., & Georgiou, G. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.03.002 · Cited by 99
Zhang, A., Hu, P., MacGregor, P. A., Xue, Y., Fan, H., Suchecki, P., Olszewski, L., & Liu, A. (2014) · Analytical Chemistry · doi:10.1021/ac404130a · Cited by 98
The role of differential IgG glycosylation in the interaction of antibodies with FcγRs in vivo
Anthony, R. M., & Nimmerjahn, F. (2011) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e328342538f · Cited by 93
Hayes, J. M., Frostell, Å., Cosgrave, E. F. J., Struwe, W. B., Potter, O. G., Davey, G. P., Karlsson, R., Annerén, C., & Rudd, P. M. (2014) · Journal of Proteome Research · doi:10.1021/pr500414q · Cited by 86 · cited 1×
“This is in accordance to the observations by Hayes et al [58,59].”
ResultInfluence of glycosylation pattern on the molecular properties of monoclonal antibodies
Zheng, K., Yarmarkovich, M., Bantog, C., Bayer, R. J., & Patapoff, T. W. (2014) · mAbs · doi:10.4161/mabs.28588 · Cited by 81
Evidence of allosteric conformational changes in the antibody constant region upon antigen binding
Oda, M. (2003) · International Immunology · doi:10.1093/intimm/dxg036 · Cited by 79 · cited 1×
“[44,45] Thus it is important to address the interaction of antibodies with Fc-receptors in the context of target binding and/or as a part of an immune complex.”
BackgroundCell Type-Specific and Site Directed N-Glycosylation Pattern of FcγRIIIa
Zeck, A., Pohlentz, G., Schlothauer, T., Peter-Katalinić, J., & Regula, J. T. (2011) · Journal of Proteome Research · doi:10.1021/pr1012653 · Cited by 78
Self-citationBrorson, K., & Jia, A. (2014) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2014.06.012 · Cited by 77 · cited 1×
“More than 40 therapeutic mAbs and mAb fragments are approved and prescribed today [1,2], the majority being of the IgG isotype.”
BackgroundGeneration and Comparative Characterization of Glycosylated and Aglycosylated Human IgG1 Antibodies
Hristodorov, D., Fischer, R., Jörißen, H., Müller‐Tiemann, B., Apeler, H., & Lindén, L. (2012) · Molecular Biotechnology · doi:10.1007/s12033-012-9531-x · Cited by 73
The biological activity of human monoclonal IgG anti-D is reduced by beta-galactosidase treatment.
Kumpel, B. M., Wang, Y., Griffiths, H. L., Hadley, A. G., & Rook, G. A. W. (1995) · PubMed · Cited by 71
Analyzing Antibody–Fc-Receptor Interactions
Nimmerjahn, F., & Ravetch, J. V. (2008) · Innate Immunity · doi:10.1007/978-1-59745-570-1_9 · Cited by 68
The biological activity of human monoclonal IgG anti-D is reduced by β-galactosidase treatment
Kumpel, B. M., Wang, Y., Griffiths, H. L., Hadley, A. G., & Rook, G. A. W. (1995) · Human Antibodies · doi:10.3233/hab-1995-6301 · Cited by 68
Glycosylation of Antibody Therapeutics: Optimisation for Purpose
Roy, J. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-407-0_13 · Cited by 59
Recognition sites on human IgG for Fcγ receptors: the role of glycosylation
Jefferis, R., Lund, J., & Goodall, M. D. (1995) · Immunology Letters · doi:10.1016/0165-2478(94)00201-2 · Cited by 44
IgG-Fc N-glycosylation at Asn297 and IgA O-glycosylation in the hinge region in health and disease
Xue, J., Zhu, L.-P., & Wei, Q. (2013) · Glycoconjugate Journal · doi:10.1007/s10719-013-9481-y · Cited by 43 · cited 1×
“It should also be mentioned, that the two heavy chains of the same IgGmolecule may carry different sugar moieties.[19,20] Multi-Angle Effector Function Analysis of Human Monoclonal IgG”
BackgroundConsequences of glycan truncation on Fc structural integrity
Buck, P. M., Kumar, S., & Singh, S. K. (2013) · mAbs · doi:10.4161/mabs.26453 · Cited by 35
Galactosylation of IgG1 modulates FcγRIIB-mediated inhibition of murine autoimmune hemolytic anemia
Yamada, K. D., Ito, K., Furukawa, J., Nakata, J., Alvarez, M., Verbeek, J. S., Shinohara, Y., & Izui, S. (2013) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.09.001 · Cited by 27
Ito, K., Furukawa, J., Yamada, K., Tran, N. L., Shinohara, Y., & Izui, S. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1302488 · Cited by 26
The glycosylation of antibody molecules: functional significance.
Jefferis, R. (1993) · PubMed · Cited by 24
Fcγ receptors: Gene structure and receptor function
Hogarth, P. M., Hulett, M. D., & Osman, N. (1992) · Immunologic Research · doi:10.1007/bf02919128 · Cited by 17
Research works printed but not linked: 27
- R Kapur, 2014, IgG-effector functions: "The Good, The Bad and The Ugly", Immunol Lett
- RM Anthony, 2012, Novel roles for the IgG Fc glycan, Ann N Y Acad Sci, 1253, 170, 10.1111/j.1749-6632.2011.06305.x · DOI · Paper page
- PM Hogarth, 2012, Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond, Nat Rev Drug Discov, 11, 311, 10.1038/nrd2909 · DOI · Paper page
- XR Jiang, 2011, Advances in the assessment and control of the effector functions of therapeutic antibodies, Nat Rev Drug Discov, 10, 101, 10.1038/nrd3365 · DOI · Paper page
- R Jefferis, 2009, Glycosylation as a strategy to improve antibody-based therapeutics, Nat Rev Drug Discov, 8, 226, 10.1038/nrd2804 · DOI · Paper page
- Y Kaneko, 2006, Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation, Science, 313, 670, 10.1126/science.1129594 · DOI · Paper page
- W Huang, 2012, Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions, J Am Chem Soc, 134, 12308, 10.1021/ja3051266 · DOI · Paper page
- TS Raju, 2008, Terminal sugars of Fc glycans influence antibody effector functions of IgGs, Curr Opin Immunol, 20, 471, 10.1016/j.coi.2008.06.007 · DOI · Paper page
- Y Mimura, 2000, The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms, Mol Immunol, 37, 697, 10.1016/S0161-5890(00)00105-X · DOI · Paper page
- PM Buck, 2013, Consequences of glycan truncation on Fc structural integrity, MAbs, 5, 904, 10.4161/mabs.26453 · DOI
- V Kayser, 2011, Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies, Biotechnol J, 6, 38, 10.1002/biot.201000091 · DOI · Paper page
- S Bohm, 2012, The role of sialic acid as a modulator of the anti-inflammatory activity of IgG, Semin Immunopathol, 34, 443, 10.1007/s00281-012-0308-x · DOI
- Y Kaneko, 2006, Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation, Science, 313, 670, 10.1126/science.1129594 · DOI · Paper page
- RM Anthony, 2012, Novel roles for the IgG Fc glycan, Ann N Y Acad Sci, 1253, 170, 10.1111/j.1749-6632.2011.06305.x · DOI · Paper page
- R Jefferis, 1993, The glycosylation of antibody molecules: functional significance, Glycoconj J, 10, 358
- R Jefferis, 2012, Isotype and glycoform selection for antibody therapeutics, Arch Biochem Biophys, 526, 159, 10.1016/j.abb.2012.03.021 · DOI · Paper page
- PM Buck, 2013, Consequences of glycan truncation on Fc structural integrity, MAbs, 5, 904, 10.4161/mabs.26453 · DOI
- R Jefferis, 2012, Isotype and glycoform selection for antibody therapeutics, Arch Biochem Biophys, 526, 159, 10.1016/j.abb.2012.03.021 · DOI · Paper page
- V Kayser, 2011, Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies, Biotechnol J, 6, 38, 10.1002/biot.201000091 · DOI · Paper page
- Y Mimura, 2000, The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms, Mol Immunol, 37, 697, 10.1016/S0161-5890(00)00105-X · DOI · Paper page
- TS Raju, 2008, Terminal sugars of Fc glycans influence antibody effector functions of IgGs, Curr Opin Immunol, 20, 471, 10.1016/j.coi.2008.06.007 · DOI · Paper page
- K Zheng, 2011, The impact of glycosylation on monoclonal antibody conformation and stability, MAbs, 3, 568, 10.4161/mabs.3.6.17922 · DOI · Paper page
- D Houde, 2010, Post-translational modifications differentially affect IgG1 conformation and receptor binding, Mol Cell Proteomics, 9, 1716, 10.1074/mcp.M900540-MCP200 · DOI · Paper page
- Y Kaneko, 2006, Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation, Science, 313, 670, 10.1126/science.1129594 · DOI · Paper page
- A Lux, 2013, Impact of immune complex size and glycosylation on IgG binding to human FcgammaRs, J Immunol, 190, 4315, 10.4049/jimmunol.1200501 · DOI · Paper page
- DC Roopenian, 2007, FcRn: the neonatal Fc receptor comes of age, Nat Rev Immunol, 7, 715, 10.1038/nri2155 · DOI · Paper page
- MK Leabman, 2013, Effects of altered FcgammaR binding on antibody pharmacokinetics in cynomolgus monkeys, MAbs, 5, 896, 10.4161/mabs.26436 · DOI · Paper page
Cited by
Pereira, N. A., Chan, K. F., Lin, P. C., & Song, Z. (2018) · mAbs · doi:10.1080/19420862.2018.1466767 · Cited by 334
“Mutations in the CH2 domain that destroyed the conserved N-glycosylation motif and hence gave rise to aglycosylated Fc resulted in complete loss of binding to most FcgRs except FcgRI.(11) Several approaches have been utilized to increase the affinity between antibody and the FcgRIII.”
BackgroundMethodAffinity of human IgG subclasses to mouse Fc gamma receptors
Dekkers, G., Bentlage, A. E. H., Stegmann, T. C., Howie, H. L., Lissenberg-Thunnissen, S., Zimring, J., Rispens, T., & Vidarsson, G. (2017) · mAbs · doi:10.1080/19420862.2017.1323159 · Cited by 293
Peschke, B., Keller, C. W., Weber, P., Quast, I., & Lünemann, J. D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00646 · Cited by 219
“Two studies reported that Fc-galactosylation results in a slight, albeit not statistically significant increase in FcγRIIIa-binding affinity and ADCC activity (16, 17).”
BackgroundFc Glycan-Mediated Regulation of Placental Antibody Transfer
Jennewein, M. F., Goldfarb, I., Dolatshahi, S., Cosgrove, C., Noelette, F. J., Krykbaeva, M., Das, J., Sarkar, A., Gorman, M. J., Fischinger, S., et al. (2019) · Cell · doi:10.1016/j.cell.2019.05.044 · Cited by 212
“Fc-Galactosylation Affects Antibody Binding to FcRn and Other Fc Receptors Contradictory roles for Fc glycosylation on FcRn binding have been reported (Bakchoul et al., 2013; Dashivets et al., 2015; Einarsdottir et al., 2013; Jansen et al., 2016b; Jefferis, 2012), including reports documenting negligible effects of Fc…”
BackgroundInfluentialWilcox, C. R., Holder, B., & Jones, C. E. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01294 · Cited by 200
“studied enzymatically engineered glycosylation variants and showed that deglycosylated IgG1 had a slightly diminished binding to FcRn, with digalactosylated IgG demonstrating superior binding than monogalactosylated and agalactosylated variants (87).”
Metadata
- Authors
- Dashivets, T., Thomann, M., Rueger, P., Knaupp, A., Buchner, J., & Schlothauer, T.
- Affiliations
- Center for Integrated Protein Science Munich (DE)
- Roche Pharma AG (Germany) (DE)
- Corresponding author
- Schlothauer, Tilman
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-12-11
- Volume
- 10
- Issue
- 12
- Pages
- e0143520
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4676693
- OpenAlex
- W2190603070
- Cited by
- 101
- References
- 69
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 8 · 2023: 12 · 2022: 7 · 2021: 13 · 2020: 12 · 2019: 10 · 2018: 8 · 2017: 14 · 2016: 7 · 2015: 1
- FWCI
- 8.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Roche Innovation Center Zurich
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Keywords
- IgG glycosylation, Fc gamma receptor, antibody effector functions, therapeutic monoclonal antibodies, FcγRI, FcγRIIa, FcγRIIB, FcγRIIIa, neonatal Fc receptor, galactosylation, sialylation, deglycosylation, immune complexes, antibody stability, antibody structure, antibody-drug conjugates
- MeSH terms
- Antibodies, Monoclonal, Antibody Affinity, Antigen-Antibody Complex, Carbohydrate Sequence, Cell Line, Chromatography, Affinity, Galactose, Glycosylation, Humans, Immunoglobulin G, Immunoglobulin Fc Fragments, Molecular Sequence Data, Protein Binding, Recombinant Proteins, Sialic Acids, Protein Engineering, Gene Expression, Receptors, IgG, Surface Plasmon Resonance, Protein Stability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.